Anti-Marinobufagenin Antibodies and Methods for Diagnosis and Treatment of Cardiovascular Disease


Hypertension is a condition characterized by persistent high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or may be associated with other primary diseases (secondary hypertension), and is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke, and kidney disease. Preeclampsia is a similar condition that occurs in 5-10% of all pregnancies (most common in first time pregnancies) and is characterized by high blood pressure, edema, and protein in the urine. Complications of preeclampsia include eclampsia (convulsions and coma) and intrauterine fetal demise.

Researchers at the National Institute on Aging (NIA) have developed monoclonal antibodies and antigen binding fragments that specifically bind marinobufagenin, a steroid that, in abundance, can exacerbate pathological states associated with fluid retention, including essential and salt-sensitive hypertension, preeclampsia, and uremic cardiomyopathy. Thus, marinobufagenin may be an appropriate target in the treatment of these disorders. In addition, NIA researchers developed methods of diagnosing hypertensive disorders, e.g., by detecting the binding of antibodies against marinobufagenin in a patient sample.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of hypertension
  • Treatment of preeclampsia
  • Methods of diagnosing hypertensive disorders
 
  • Treatment methods claimed by the patent span a wide array of indications
  • Efficient methods of diagnosing hypertensive disorders


Inventors:

Alexei Bagrov (NIA)  ➽ more inventions...

Olga Fedorova (NIA)  ➽ more inventions...

Edward Lakatta (NIA)  ➽ more inventions...

Andrey Simbirtsev

Alexander Kotov

Nikolai Kolodkin


Intellectual Property:
U.S. Pat: 8,038,997 issued 2011-10-18
PCT Application No. PCT/US2006/024918
US Application No. 11/993,309

Collaboration Opportunity:

The National Institute on Aging, Laboratory of Cardiovascular Science, seeks licensing partners and statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these antibodies.


Licensing Contact:
Richard Girards, J.D., M.B.A.
Email: richard.girards@nih.gov
Phone: 240-276-6825

OTT Reference No: E-092-2004/0
Updated: Jun 29, 2017